The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review-Reference-Cited by-同舟云学术

The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative review

Published:2024-01-15 Issue: Volume: Page:
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Sloan Lance¹²^ORCID,Cheng Alice Y. Y.³,Escalada Javier⁴⁵⁶,Haluzík Martin⁷,Mauricio Didac⁸⁹¹⁰^ORCID

Affiliation:

1. Texas Institute for Kidney and Endocrine Disorders Lufkin Texas USA

2. University of Texas Medical Branch Galveston Texas USA

3. Trillium Health Partners & Unity Health University of Toronto Toronto Ontario Canada

4. Department of Endocrinology and Nutrition Clínica Universidad de Navarra Pamplona Spain

5. Center for Biomedical Research in Physiopathology of Obesity and Nutrition (CIBERobn) Instituto de Salud Carlos III Madrid Spain

6. Instituto de Investigación Sanitaria de Navarra (IdiSNA) Pamplona Spain

7. Diabetes Centre, Institute for Clinical and Experimental Medicine Prague Czech Republic

8. Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM) Instituto de Salud Carlos III Barcelona Spain

9. Department of Endocrinology and Nutrition CIBERDEM, Hospital de la Santa Creu i Sant Pau & Sant Pau Biomedical Research Institute (IIB Sant Pau) Barcelona Spain

10. Faculty of Medicine University of Vic (UVIC/UCC) Vic Spain

Abstract

AbstractThe majority of cases of chronic kidney disease (CKD) worldwide are driven by the presence of type 2 diabetes (T2D), resulting in an increase in CKD rates over the past few decades. The existence of CKD alongside diabetes is associated with increased burden of cardiovascular disease and increased risk of death. Optimal glycaemic control is essential to prevent progression of CKD, but achieving glycaemic targets in people with CKD and diabetes can be challenging because of increased risk of hypoglycaemia and limitations on glucose‐lowering therapeutic options. This review considers the challenges in management of T2D in people with impaired kidney function and assesses evidence for use of basal insulin analogues in people with CKD.

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference68 articles.

1. The Evolution of Insulin and How it Informs Therapy and Treatment Choices

2. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

3. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

4. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults

5. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. KDIGO 2022 clinical practice guideline for diabetes Management in Chronic Kidney Disease;Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group;Kidney Int,2022